Sage Therapeutics Inc (SAGE) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Sage Therapeutics, Inc. (NASDAQ: SAGE), today announced that the Company will participate in a fireside chat at the Piper Sandler 36th Annual...

Form 8-K - Current report

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease

The Phase 2 DIMENSION Study did not meet its primary endpoint Dalzanemdor was generally well-tolerated; no new safety signals were observed Based...

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates

Achieved $11 million in ZURZUVAE® (zuranolone) collaboration revenue during the third quarter of 2024 (50% of the net revenue recorded by...

Sage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SAGE

Sage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights...

Shareholders that lost money on Sage Therapeutics, Inc.(SAGE) should contact The Gross Law Firm about pending Class Action - SAGE

Shareholders that lost money on Sage Therapeutics, Inc.(SAGE) should contact The Gross Law Firm about pending...